Monoclonal antibodies Archives

News and Trends 1 Jun 2023

Sanofi drug reduces disease activity in relapsing MS

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […]

June 1, 2023 - 4 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 14 Apr 2023

TORL BioTherapeutics launches with $158M to target cancer

TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a $158 million Series B financing. TORL’s pipeline of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) were discovered in the laboratory of scientific co-founder Dennis Slamon, professor of medicine, and chief of […]

April 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding from venture capital company AdBio partners. The funds will be used to conduct additional in vivo proofs of concept and select a lead candidate. Calida […]

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 17 Mar 2023

Purple Biotech sees positive results from cancer study

Purple Biotech Ltd. has released new results from exploratory analyses conducted as part of a phase 1 dose escalation study that assessed the safety and tolerability of nivolumab and CM24, which is a monoclonal antibody. Purple Biotech is a clinical-stage company developing first-in-class therapies that harness the tumor microenvironment (TME) to overcome tumor immune evasion […]

March 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Disc Medicine raises $62.5M for hematology programs

Disc Medicine, Inc., a U.S. clinical-stage biopharma company focused on the discovery, development and commercialization of treatments for patients suffering from serious hematologic diseases, has entered into a securities purchase agreement with investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering. The financing was led by Bain Capital Life […]

February 14, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 10 Feb 2023

Janssen reports positive topline phase 2 HDFN results

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the proof-of-concept phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious and rare condition that can cause life-threatening anemia in the […]

February 10, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease

BioArctic AB’s partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab. Lecanemab, known as LEQEMBI in the U.S., is an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed […]

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

Dupixent gets EU nod for children with severe atopic dermatitis

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent (dupilumab), recommending expanded approval in the European Union (EU) to treat severe atopic dermatitis in children six months to five years old who are candidates for systemic therapy. The European Commission is expected to announce a final […]

January 27, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Positive Dupixent eosinophilic esophagitis phase 3 results

The New England Journal of Medicine has published results from a positive phase 3 trial showing adults and adolescents treated with Dupixent (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE), which were sustained for up to one year. EoE is a chronic, progressive inflammatory disease that damages the […]

December 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Watch: Adrenomed tackling huge issue of sepsis

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Its mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead […]

December 19, 2022 - 1 minutemin - By Jim Cornall

News and Trends 16 Dec 2022

Astellas gastric cancer drug meets phase 3 primary endpoint

Astellas Pharma Inc. has announced positive topline results from the phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin). Zolbetuximab is an investigational first-in-class claudin-18.2 (CLDN18.2) targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials […]

December 15, 2022 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Monoclonal antibodies

Sanofi drug reduces disease activity in relapsing MS

TORL BioTherapeutics launches with $158M to target cancer

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Purple Biotech sees positive results from cancer study

Disc Medicine raises $62.5M for hematology programs

Janssen reports positive topline phase 2 HDFN results

EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease

Dupixent gets EU nod for children with severe atopic dermatitis

Positive Dupixent eosinophilic esophagitis phase 3 results

Watch: Adrenomed tackling huge issue of sepsis

Astellas gastric cancer drug meets phase 3 primary endpoint

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!